Catherine Reenaers1, Peter Bossuyt2, Pieter Hindryckx3, Hilde Vanpoucke4, Anneline Cremer5, Filip Baert6. 1. Department of Gastroenterology, CHU Sart Tilman, Liège, Belgium. 2. Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium. 3. Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium. 4. Department of Laboratory Medicine, AZ Delta, Roeselare-Menen, West-Vlaanderen, Belgium. 5. Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Bruxelles, Belgium. 6. Department of Gastroenterology, AZ Delta, Roeselare, Belgium.
Abstract
BACKGROUND: Despite many publications regarding the role of faecal calprotectin (FC) in inflammatory bowel disease (IBD), clear recommendations for its use in clinical practice are currently lacking in the literature. AIM: The aim of this article is to provide practical guidance for clinicians for the use of FC in the detection and management of patients with IBD. METHODS: All relevant publications were analysed and practical statements were proposed based on a Delphi consensus approach. RESULTS: Different commercial assays have been developed but international standardisation is lacking. FC can help in the diagnosis process of IBD. In IBD, FC can predict response to therapy, detect subclinical inflammation and help to drive treatment decisions to achieve better endoscopic and clinical outcomes. After Crohn's surgery FC can identify patients with early endoscopic recurrence. CONCLUSION: Although major therapeutic changes should not be based on FC alone, FC is a valuable tool to optimise the care for IBD patients.
BACKGROUND: Despite many publications regarding the role of faecal calprotectin (FC) in inflammatory bowel disease (IBD), clear recommendations for its use in clinical practice are currently lacking in the literature. AIM: The aim of this article is to provide practical guidance for clinicians for the use of FC in the detection and management of patients with IBD. METHODS: All relevant publications were analysed and practical statements were proposed based on a Delphi consensus approach. RESULTS: Different commercial assays have been developed but international standardisation is lacking. FC can help in the diagnosis process of IBD. In IBD, FC can predict response to therapy, detect subclinical inflammation and help to drive treatment decisions to achieve better endoscopic and clinical outcomes. After Crohn's surgery FC can identify patients with early endoscopic recurrence. CONCLUSION: Although major therapeutic changes should not be based on FC alone, FC is a valuable tool to optimise the care for IBD patients.
Authors: Karin Amcoff; Mats Stridsberg; Maria Lampinen; Anders Magnuson; Marie Carlson; Jonas Halfvarson Journal: Scand J Gastroenterol Date: 2016-11-24 Impact factor: 2.423
Authors: Jean-Frederic Colombel; Remo Panaccione; Peter Bossuyt; Milan Lukas; Filip Baert; Tomas Vaňásek; Ahmet Danalioglu; Gottfried Novacek; Alessandro Armuzzi; Xavier Hébuterne; Simon Travis; Silvio Danese; Walter Reinisch; William J Sandborn; Paul Rutgeerts; Daniel Hommes; Stefan Schreiber; Ezequiel Neimark; Bidan Huang; Qian Zhou; Paloma Mendez; Joel Petersson; Kori Wallace; Anne M Robinson; Roopal B Thakkar; Geert D'Haens Journal: Lancet Date: 2017-10-31 Impact factor: 79.321
Authors: Erik Mooiweer; Mirjam Severs; Marguerite E I Schipper; Herma H Fidder; Peter D Siersema; Robert J F Laheij; Bas Oldenburg Journal: J Crohns Colitis Date: 2014-11-26 Impact factor: 9.071
Authors: Pauliina Molander; Martti Färkkilä; Ari Ristimäki; Kimmo Salminen; Helena Kemppainen; Timo Blomster; Ritva Koskela; Airi Jussila; Henna Rautiainen; Markku Nissinen; Johanna Haapamäki; Perttu Arkkila; Urpo Nieminen; Juha Kuisma; Jari Punkkinen; Kaija-Leena Kolho; Harri Mustonen; Taina Sipponen Journal: J Crohns Colitis Date: 2015-01 Impact factor: 9.071
Authors: L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: Thomas Greuter; Frédéric Porchet; Manuel B Braga-Neto; Jean-Benoit Rossel; Luc Biedermann; Philipp Schreiner; Michael Scharl; Alain M Schoepfer; Ekaterina Safroneeva; Alex Straumann; Gerhard Rogler; Stephan R Vavricka Journal: United European Gastroenterol J Date: 2020-12 Impact factor: 4.623
Authors: Alberto Lué; Gonzalo Hijos; Carlos Sostres; Alba Perales; Mercedes Navarro; Maria Victoria Barra; Barbara Mascialino; Carmen Andalucia; Juan José Puente; Ángel Lanas; Fernando Gomollon Journal: Therap Adv Gastroenterol Date: 2020-05-18 Impact factor: 4.409
Authors: Gonzalo Hijos-Mallada; Alberto Lué; Raul Velamazan; Nuria Saura; Carlos Abril; Marta Lorenzo; Mercedes Navarro; Eduardo Chueca; Samantha Arechavaleta; Fernando Gomollón; Ángel Lanas; Carlos Sostres Journal: Front Med (Lausanne) Date: 2021-06-04
Authors: José María Paredes; Tomás Ripollés; Ángela Algarra; Rafael Diaz; Nadia Moreno; Patricia Latorre; María Jesús Martínez; Pilar Llopis; Antonio López; Eduardo Moreno-Osset Journal: Intest Res Date: 2022-03-15